ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H

As of December 31, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H carries a market capitalization of 2.52B, placing it among publicly traded companies globally. Its enterprise value stands at 1.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H's next confirmed earnings release is scheduled for March 30, 2027.

As of December 31, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 431.51M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H maintains a current ratio of 3.83, meaning it holds 3.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H's stock has declined approximately 70.05% over the past 52 weeks. The 50-day moving average sits at 3.37, while the 200-day moving average is 4.08.

As of December 31, 2025, ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H holds 1.13B in cash and equivalents against 253.77M in total debt, resulting in a net debt position of -518.16M. Total book value stands at 880.78M, with working capital of 869.32M providing operational flexibility.